Provided by Tiger Trade Technology Pte. Ltd.

Seelos Therapeutics, Inc.

0.3900
0.0000
Volume:- -
Turnover:- -
Market Cap:226.59K
PE:0.01
High:0.3900
Open:0.3900
Low:0.3900
Close:0.3900
52wk High:0.3900
52wk Low:0.3900
Shares:581.00K
Float Shares:578.90K
Volume Ratio:2.03
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):47.06
EPS(LYR):-989.5254
ROE:-584.20%
ROA:-261.11%
PB:-0.01
PE(LYR):0.00

Loading ...

Company Profile

Company Name:
Seelos Therapeutics, Inc.
Exchange:
OTCQB
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.